Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 10—October 2013

Recurrent Bordetella holmesii Bacteremia and Nasal Carriage in a Patient Receiving Rituximab

Liem Binh Luong Nguyen, Loïc Epelboin, Jean Gabarre, Marylin Lecso, Sophie Guillot, François Bricaire, Eric Caumes, and Nicole GuisoComments to Author 
Author affiliations: Groupe Hospitalier Pitié-Salpêtrière, Paris, France (L.B.Luong Nguyen, L. Epelboin, J. Gabarre, M. Lecso, F. Bricaire, E. Caumes); Université Paris, Paris (L. Epelboin, F. Bricaire, E. Caumes); and Institut Pasteur, Paris (S. Guillot, N. Guiso)

Main Article


Antimicrobial resistance profile of Bordetella holmesii isolates in vitro, France,, December 2010–March 2011*

Antimicrobial agent
Antimicrobial drug MICs†, μg/mL, by isolate‡
Blood, d 1
Blood, d 24
Blood, d 33
Blood, d 74
NPS, d 105
Amoxicillin <2 <2 NA# 16 <2
Cefoxitin <8 >256 >256 >256 >256
Cefotaxime >32 >32 >32 >32 >32
Nalidixic acid <16 <16 <16 64 >256
Trimethroprim >32 >32 >32 >32 >32
Sulfamethoxazole >512 >512 >512 >512 >512

*MICs corresponding to a drug resistance, which may reflect the general interpretation for nonfermenting bacteria, are in boldface. NPS, nasopharyngeal swab; NA, no available data.
†MICs were determined by E-test on Bordet–Gengou agar.
‡Site and day (d) of collection of isolate.

Main Article

Page created: September 16, 2013
Page updated: September 16, 2013
Page reviewed: September 16, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.